Last10K.com

Brainstorm Cell Therapeutics Inc. (BCLI) SEC Filing 8-K Material Event for the period ending Thursday, February 1, 2018

Brainstorm Cell Therapeutics Inc.

CIK: 1137883 Ticker: BCLI

View differences made from one to another to evaluate Brainstorm Cell Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Brainstorm Cell Therapeutics Inc..

Continue

Assess how Brainstorm Cell Therapeutics Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Brainstorm Cell Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools
Ticker: BCLI
CIK: 1137883
Form Type: 8-K Corporate News
Accession Number: 0001144204-18-005749
Submitted to the SEC: Mon Feb 05 2018 4:50:31 PM EST
Accepted by the SEC: Mon Feb 05 2018
Period: Thursday, February 1, 2018
Industry: Biological Products No Disgnostic Substances
Events:
  1. Event for Officers

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/bcli/0001144204-18-005749.htm